It means it should be framed as unfinished
Most beneficial during severe caloric restriction or for older adults
Tirzepatide is a dual GLP-1/GIP receptor agonist, currently FDA-approved and available clinically
Coskun and colleagues (Molecular Metabolism, 2018) reported the foundational characterisation: tirzepatide binds the human GIP receptor with Ki 0.135 nM and the human GLP-1 receptor with Ki 4.7 nM
doi: 10.1136/heartjnl-2019-316376 [PubMed] [CrossRef] [Google Scholar] Cosentino F., et al., 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
The SURPASS program demonstrated HbA1c reductions of 2.0-2.3% at the 15mg dose, with many participants achieving HbA1c below 5.7% (the threshold for normal blood sugar)